Related references
Note: Only part of the references are listed.Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Igor Stukalin et al.
ONCOLOGIST (2023)
Regional variability of melanoma incidence and prevalence in Hungary. Epidemiological impact of ambient UV radiation and socioeconomic factors.
Eszter A. Janka et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2022)
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Claus Garbe et al.
EUROPEAN JOURNAL OF CANCER (2022)
Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma
Elisa A. Rozeman et al.
CLINICA CHIMICA ACTA (2022)
Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis
Jingjing Zhao et al.
FRONTIERS IN IMMUNOLOGY (2022)
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry
Daan Jan Willem Rauwerdink et al.
CANCERS (2022)
Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma
Florentia Dimitriou et al.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)
Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma
Ke-Jia Wu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Predictive Performance of Serum S100B Versus LDH in Melanoma Patients: A Systematic Review and Meta-Analysis
Eszter Anna Janka et al.
FRONTIERS IN ONCOLOGY (2021)
Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma
Se Ryeong Jang et al.
JAMA NETWORK OPEN (2021)
Immune Responses against Disseminated Tumor Cells
Ling Peng et al.
CANCERS (2021)
Unraveling the Wide Spectrum of Melanoma Biomarkers
Antonios Revythis et al.
DIAGNOSTICS (2021)
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
Lisa Haas et al.
NATURE CANCER (2021)
Significance of 5-S-Cysteinyldopa as a Marker for Melanoma
Kazumasa Wakamatsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma
Teresa Amaral et al.
CANCERS (2020)
RAGE Signaling in Melanoma Tumors
Olamide T. Olaoba et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
Valsamo Anagnostou et al.
CELL REPORTS MEDICINE (2020)
Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment
Ricardo Perez-Tomas et al.
CANCERS (2020)
Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy
Michael Lattanzi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy
Michael Lattanzi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
The S100B story: from biomarker to active factor in neural injury
Fabrizio Michetti et al.
JOURNAL OF NEUROCHEMISTRY (2019)
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAFV600-mutated Metastatic Melanoma
Yibing Yan et al.
CLINICAL CANCER RESEARCH (2019)
S100 proteins: Diagnostic and prognostic biomarkers in laboratory medicine
Claus W. Heizmann
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
Increasing melanoma incidence in the elderly in North-East Hungary: is this a more serious problem than we thought?
Eszter A. Janka et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2019)
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
Nikolaus B. Wagner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis
T. Gambichler et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Nikolaus B. Wagner et al.
BRITISH JOURNAL OF CANCER (2018)
Ultraviolet radiation-mediated development of cutaneous melanoma: An update
Gabriella Emri et al.
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY (2018)
Biomarkers for immune Checkpoint inhibitors in Melanoma
Shigehisa Kitano et al.
FRONTIERS IN ONCOLOGY (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA
Rossella Salemi et al.
FRONTIERS IN PHARMACOLOGY (2018)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
Adi Nosrati et al.
BRITISH JOURNAL OF CANCER (2017)
Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy
Joana Felix et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients
Christoffer Gebhardt et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2016)
Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
Fausto Petrelli et al.
ACTA ONCOLOGICA (2015)
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis
Mitchell S. Stark et al.
EBIOMEDICINE (2015)
Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients
Miguel F. Sanmamed et al.
CLINICA CHIMICA ACTA (2014)
BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
Victoria J. Mar et al.
CLINICAL CANCER RESEARCH (2013)
Protein and non-protein biomarkers in melanoma: a critical update
Nadine Tandler et al.
AMINO ACIDS (2012)
The current status of S-100B as a biomarker in melanoma
S. Kruijff et al.
EJSO (2012)
Importance of glycolysis and oxidative phosphorylation in advanced melanoma
Jonhan Ho et al.
MOLECULAR CANCER (2012)
A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients
Pierre Vereecken et al.
DERMATOLOGY RESEARCH AND PRACTICE (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Detection of melanoma relapse: First comparative analysis on imaging techniques versus S100 protein
Mirjam Beyeler et al.
DERMATOLOGY (2006)
S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma
R Hatpio et al.
CLINICAL BIOCHEMISTRY (2004)
Reference values for serum S-100B protein depend on the race of individuals
O Ben Abdesselam et al.
CLINICAL CHEMISTRY (2003)
Share Paper
